PRAME and hematologic disorder: PRAME has been recently introduced as a prognostic and/or oncogenic biomarker of various cancer types, including melanocytic neoplasms [22], invasive breast carcinoma [23], lung adenocarcinoma [24], lung squamous cell carcinoma [25], and hematological malignancies [26].